Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles
Jan‐Niklas Eckardt(Else Kröner-Fresenius-Stiftung), Jan Moritz Middeke(Klinik und Poliklinik für Psychotherapie und Psychosomatik), Cristina Sauerland(University of Münster), Karsten Spiekermann(German Cancer Research Center), Sebastian Stasik, Utz Krug(Klinikum Leverkusen), Wolfgang E. Berdel(University of Münster), Karsten Wendt, Christoph Röllig(University Hospital Carl Gustav Carus), Martin Bornhäuser(Klinik und Poliklinik für Psychotherapie und Psychosomatik), Klaus H. Metzeler, Carsten Müller‐Tidow(University of Cologne), Wolfgang Hiddemann(The University of Texas MD Anderson Cancer Center), Claudia D. Baldus(German Cancer Research Center), Dennis Görlich(University of Münster), Friedrich Stölzel(University Hospital Carl Gustav Carus), Julia-Annabell Georgi(University Hospital Carl Gustav Carus), Peter Heisig(Institute of Software), Jiřı́ Mayer(University Hospital Brno), Mathias Hänel(Klinikum Chemnitz), Christoph Schliemann(University Hospital Münster), Jan Braess, Frank Kroschinsky(University Hospital Carl Gustav Carus), Maher Hanoun(Essen University Hospital), Uwe Platzbecker(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Stefan W. Krause(Universitätsklinikum Erlangen), Tobias Herold(German Cancer Research Center), Hubert Serve(University Hospital Münster), Martin Kaufmann(Robert Bosch Hospital), Kerstin Schäfer‐Eckart(Nuremberg Hospital), Johannes Schetelig(German National Bone Marrow Donor Registry), Bernhard J. Woermann(Charité - Universitätsmedizin Berlin), Christian Thiede(Klinik und Poliklinik für Psychotherapie und Psychosomatik)
Cited by 18
Related Papers
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3k
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
|Journal of Clinical Oncology|2003|2.7k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k